The aim of the study was to assess plasma concentrations of darunavir/ritonavir and raltegravir in older patients compared with younger patients with HIV-1 infection.
Introduction
The advent of combination antiretroviral therapy (cART) and its widespread availability have greatly extended the lifespan of patients with HIV-1 infection, transforming this infectious disease into a manageable chronic condition and resulting in a growing population of older HIV-positive individuals [1, 2] . As a result of the prolonged life expectancy and increased mean age of the HIV-positive population, noninfectious comorbidities (such as cardiovascular disease, liver disease, renal disease and malignancies) are today the most frequent cause of death among HIV-infected persons [3, 4] .
The individual-based model of the national Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort suggests that the median age of HIV-infected subjects on cART will increase from 43.9 years in 2010 to 56.6 years in 2030, with the percentage of HIV-positive persons aged 50 years or older increasing from 28% to 73%. On the basis of this projection, in 2030, 84% of HIV-infected patients will have at least one noninfectious comorbidity, and about one-third will have three or more noninfectious comorbidities [5] .
The effects of old age on the outcomes of cART and the natural history of HIV infection are not completely understood, because elderly people are underrepresented in all clinical trials and the available data are still limited. Some observational studies show a slower and more limited recovery of CD4 lymphocyte count, but faster and better virological suppression, after initiation of cART in patients aged 50 years or older. Moreover, these subjects usually show higher rates of mortality in the first year of treatment, with a greater incidence of cART-related adverse events (such as renal toxicity, liver toxicity, cardiovascular disease, peripheral neuropathy and bone fractures) [6] [7] [8] [9] .
The physiological effects of aging may certainly explain the increased susceptibility of the elderly population to drug-related toxicity and to many drugÀdrug interactions, but to date there are very few studies evaluating the pharmacokinetics of antiretroviral agents in older patients.
The possible variations in antiretroviral pharmacokinetics in older individuals result in a wide range of individual patient drug exposures and have led to an increasing interest in the clinical use of therapeutic drug monitoring (TDM) as an approach to individualize drug dosing in elderly people [10] .
The aim of this study was to evaluate the plasma concentrations of darunavir/ritonavir and raltegravir (all in combination with tenofovir/emtricitabine) in HIV-infected patients ≥ 60 years old in comparison with those ≤ 40 years old.
Methods
In this observational, open-label study, HIV-infected outpatients attending the Division of Infectious Diseases of S. Orsola-Malpighi Hospital in Bologna between January 2013 and December 2015, who were aged ≤ 40 years or ≥ 60 years and who were on stable antiretroviral treatment including tenofovir/emtricitabine (300/200 mg daily) plus darunavir/ritonavir (800/100 mg daily) or raltegravir (400 mg twice daily) for at least 4 weeks, were asked to participate. The study was approved by the Ethics Committee of S. Orsola-Malpighi Hospital, and written informed consent was obtained from each patient before enrolment.
The primary endpoint of the study was the plasma concentrations of darunavir, ritonavir and raltegravir in older patients (aged ≥ 60 years) compared with younger patients (aged ≤ 40 years). A secondary endpoint was the possible correlation between the drugs' plasma concentrations and some drug-related adverse events. Moreover, we also considered as a secondary endpoint the number of patients with subtherapeutic or potentially toxic plasma concentrations.
On the day of blood sampling for pharmacokinetic analysis, epidemiological data (sex, age, race, risk factors for HIV infection and HIV disease stage) and anthropometric measurements [body weight, height and body mass index (BMI)] were obtained. At the same time, a clinical evaluation was performed, with CD4 lymphocyte count and plasma HIV viral load being determined, liver and renal function tests carried out, and serum concentrations of glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and insulin measured. The HIV RNA viral load was determined using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (Roche Diagnostics, GmbH, Mannheim, Germany), in accordance with the manufacturer's instructions, and was expressed as HIV-1 RNA copies/mL of plasma, with a lower detection limit of 20 copies/mL.
Exclusion criteria were age < 18 years, a recent history of alcohol or drug abuse, acute or chronic viral hepatitis, liver cirrhosis, recent and uncontrolled opportunistic disease, acute severe disease, renal dysfunction (serum creatinine > 1.2 mg/dL), diabetes mellitus, pregnancy or breast feeding, adherence to antiretroviral treatment < 95%, current lipid-lowering or antidiabetic treatment, and concomitant administration of medications or herbal supplements known to affect darunavir/ritonavir or raltegravir pharmacokinetics (such as St John's wort). Adherence to the current therapy was carefully checked on out-patient visits using self-report questionnaires.
Darunavir/ritonavir therapy was administered in tablet form at the standard dose of 800/100 mg once daily at breakfast time and after a standardized continental breakfast. Raltegravir was also administered in tablet form at the standard dose of 400 mg twice daily, at breakfast and at supper time. We assessed the trough plasma concentration (C trough ) of darunavir, ritonavir and raltegravir, which is the standard parameter used to define the therapeutic range of these drugs. The C trough of darunavir, ritonavir and raltegravir was assessed at steady state (> 4 weeks after treatment initiation), with blood samples obtained before the morning dose and 23-25 h after the previous morning dose of darunavir/ritonavr and 11-13 h after the previous evening dose of raltegravir.
The exact times of the predose sample and of the previous morning or evening intake were recorded, in order to ensure accurately timed blood sampling. C trough was considered to be within an acceptable sampling timeframe if it fell within a defined time range: for darunavir and ritonavir, every 24 h within 23-25 h after the last dose, and for raltegravir, every 12 h within 11-13 h after the last dose.
One blood sample was available for each patient. Blood samples were collected in 3.0-mL Vacuette (Preanalitica s.r.l., Bergamo, Italy) EDTA-containing tubes and were centrifuged (at 600 g for 10 min) to obtain plasma samples within 2 h of collection. The plasma samples were frozen at À20°C and were sent on dry ice to the Central Laboratory of the S. Orsola-Malpighi Hospital to assess the C trough values of the antiretroviral drugs. After thawing, HIV was inactivated at 56°C for 30 min, then the plasma samples were extracted and subjected to validated high-performance liquid chromatography (HPLC)Àtandem mass spectrometry, following the method described by Dickinson et al. [11] with modifications as described in other studies for the determination of darunavir/ritonavir [12] and raltegravir [13] plasma concentrations. An internal standard (cimetidine) and acetonitrile (400 lL) were added to aliquots (100 lL) of calibrators, quality controls, and patient ultrafiltrate. After mixing, centrifugation, and addition of ammonium formate buffer (100 lL; 20 mM), samples were analysed by HPLCÀtandem mass spectrometry (10 lL). Fragmentation of parent molecules into daughter ions occurred by electrospray ionization; ions were separated according to their m/z ratio and quantified by the intensity of their respective daughter ions. The standard curves for darunavir, ritonavir and raltegravir were linear within the range of 40 to 12 000 ng/ mL in plasma, with a lower limit of detection of 20 ng/ mL for all drugs. Intra-assay coefficients of variation for darunavir, ritonavir and raltegravir quality control (QC) concentrations were 9.4%, 9.6% and 9.2%, respectively, for the low QC concentration (60 ng/mL), and 8.2%, 8.8% and 8.6%, respectively, for the high QC concentration (10 000 ng/mL). Interassay coefficients of variation were 9.3%, 9.9% and 9.4% for darunavir, ritonavir and raltegravir, respectively, for the low QC concentration, and 7.5%, 8.6% and 8.9%, respectively, for the high QC concentration. The corresponding accuracy ranged between 92% and 106% for darunavir, 95% and 108% for ritonavir, and 91% and 106% for raltegravir.
The median C trough of darunavir (at 800 mg daily in combination with ritonavir 100 mg daily) was 1340 ng/mL, the range of the darunavir C trough (at 600 mg twice daily in combination with ritonavir 100 mg twice daily) in clinical studies was 1255-7368 ng/mL, and the 50% inhibitory concentration (IC 50 ) of darunavir for wild-type virus is 55 ng/mL. We therefore considered a C trough < 55 ng/mL as a subtherapeutic concentration and a C trough > 7368 as a potentially toxic concentration [14] [15] [16] .
The median C trough of raltegravir was 72 ng/mL, the range of the raltegravir C trough (at 400 mg twice daily) in clinical studies was 29-118 ng/mL, and the IC 50 of raltegravir for wild-type virus is 3.2 ng/mL. We therefore considered a C trough < 3.2 ng/mL as a subtherapeutic concentration and a C trough > 118 as a potentially toxic concentration [14, 17] . These concentrations were used as a guideline for analysing the pharmacological data.
The statistical analysis was performed considering darunavir, ritonavir and raltegravir concentrations separately. Variables with a normal distribution were described as mean [standard deviation (SD)] and compared using an unpaired t-test. Median and interquartile range were employed to describe variables that did not follow a normal distribution and these were compared with the MannÀWhitney nonparametric test. Percentages were compared with the chi-squared test or Fisher's exact test, as appropriate. The C trough values of darunavir, ritonavir and raltegravir were described as the geometric mean, and inter-individual variability in drug concentrations was expressed as the coefficient of variation (CV%), which was calculated by dividing the SD by the mean. The darunavir, ritonavir and raltegravir C trough values were compared in older and younger patients using the geometric mean ratio (GMR) and the 95% confidence interval (CI).
In order to account for the potential influences of sex, BMI and albumin concentrations in plasma on drug exposure, multiple regression models including these variables were tested. Variables showing a statistically significant association with increased plasma levels of drugs in the univariate analysis (P < 0.10) were included in a multivariate logistic regression model using a stepwise backward elimination to determine the influence of, and adjust for confounding among, factors of interest. A P-value of < 0.05 was considered significant.
The minimum sample size to detect a difference of 30% or greater in the C trough of darunavir and raltegravir between older and younger patients was 15 in each group, when accepting an a risk of 0.005 and a b risk of 0.20 [18, 19] . Similarly, the minimum sample size to detect a difference of 30% or greater in the C trough of darunavir and raltegravir between patients with and those without a specific adverse event was 15 in each group, when accepting an a risk of 0.005 and a b risk of 0.20.
Results
A total of 88 adult HIV-positive patients were enrolled in the study. All these patients were receiving tenofovir/ emtricitabine (300/200 mg daily) and they were stratified into two groups with regard to the third antiretroviral agent: darunavir/ritonavir (800/100 mg daily) in 46 and raltegravir (400 mg twice daily) in 42 individuals. In each patient group, two subgroups were identified with regard to age. Among patients taking darunavir/ritonavir, there were 21 older and 25 younger patients. Among those taking raltegravir, there were 19 older and 23 younger patients. The demographic, anthropometric, clinical, and laboratory characteristics of the enrolled patients are summarized in Table 1 .
All patients had been taking the current antiretroviral regimen for at least 4 weeks, so they were at steady state for all current antiretroviral drugs. The mean (AESD) duration of the current antiretroviral therapy was 38.5 (AE19.4) months, while the mean total duration of antiretroviral therapy was 8.8 (AE3.7) years. None of the enrolled patients were taking concomitant medications with potential pharmacokinetic interactions with darunavir/ritonavir or raltegravir.
There were no statistically significant differences between patients treated with darunavir/ritonavir and those treated with raltegravir in terms of demographic, anthropometric, and HIV-related clinical and laboratory characteristics. The only difference was in lipid parameters: the mean (AESD) plasma concentration of triglycerides was significantly higher in subjects receiving darunavir/ritonavir (233 AE 109 mg/dL) than in those treated with raltegravir (194 AE 88 mg/dL; P = 0.022).
Immunovirological parameters were also comparable between the two groups. Plasma HIV viral load was undetectable (< 20 copies/mL) in 45 out of 46 (97.8%) patients in the darunavir/ritonavir group and in 41 out of 42 (97.6%) patients in the raltegravir group (P = 0.887). The mean (AESD) CD4 T-lymphocyte count was 517 AE 198 cells/lL in the darunavir/ritonavir group and 504 AE 182 cells/lL in the raltegravir group (P = 0.688). In both darunavir/ritonavir-treated patients and raltegravir-treated patients, older subjects had a significantly longer mean total duration of cART, a significantly lower mean CD4 T-lymphocyte count, and significantly greater mean values of serum insulin and creatinine than the respective younger patients ( Table 1) .
The mean (AESD) time between sampling and drug quantification was 1.32 (AE0.58) h.
Plasma concentrations of the three drugs showed high inter-individual variability, but almost all samples were found to be within the therapeutic plasma level range: all the 46 darunavir samples, and 40 of the 42 (95.2%) raltegravir samples.
The geometric mean plasma C trough (CV%) of darunavir was 2017 ng/mL (145%), and was significantly higher in older patients than in younger patients, as shown in Table 2 . Overall, the mean darunavir C trough (CV%) was significantly higher in female patients (2144 ng/mL; 143%) than in male patients (1991 ng/mL; 128%; GMR 1.48; 95% CI: 1.21-1.89; P = 0.041), in patients with BMI < 24 kg/m 2 (2219 ng/mL; 119%) than in those with BMI ≥ 24 kg/m 2 (1887 ng/mL; 152%; GMR 1.57; 95% CI:
1.29-1.78; P = 0.039), and in patients with albumin concentration < 3.5 g/dL (2144 ng/mL; 167%) than in those with albumin concentration ≥ 3.5 g/dL (1914 ng/mL; 148%; GMR 1.66; 95% CI: 1.26-1.98; P = 0.019). The darunavir C trough also remained significantly higher in older than in younger patients when subjects were stratified with regard to sex, BMI or serum albumin concentration (Table 2 ). Neither older nor younger patients in the darunavir/ritonavir group presented a subtherapeutic or a potentially toxic C trough of darunavir. A potential correlation between plasma concentration and some drug-related adverse events was investigated for darunavir. The geometric mean plasma C trough (CV%) of darunavir was 1997 ng/mL (162%) in 11 subjects with hypertriglyceridaemia and 2055 ng/mL (148%) in 35 persons without this disturbance, and this difference was not statistically significant (GMR 0.62; 95% CI: 0.31-1.09; P = 0.612). The geometric mean plasma C trough (CV%) of darunavir was 2017 ng/mL (141%) in nine subjects with diarrhoea and 2088 ng/mL (162%) in 37 persons without this disturbance, and this difference was not statistically significant (GMR 0.48; 95% CI: 0.24-0.78; P = 0.779).
The geometric mean plasma C trough (CV%) of ritonavir was 245 ng/mL (134%), and was significantly higher in older patients than in younger patients, as shown in Table 2 . Overall, the ritonavir C trough (CV%) was significantly higher in female patients (264 ng/mL; 151%) than in male patients (231 ng/mL; 158%; GMR 1.53; 95% CI: 1.26-2.07; P = 0.021), in patients with BMI < 24 kg/m 2 (265 ng/mL; 128%) than in those with BMI ≥ 24 kg/m 2 (227 ng/mL; 158%; GMR 1.66; 95% CI: 1.17-1.98; P = 0.009), and in patients with albumin concentration < 3.5 g/dL (258 ng/mL; 147%) than in those with albumin concentration ≥ 3.5 g/dL (231 ng/mL; 141%; GMR 1.61; 95% CI: 1.33-1.88; P = 0.015). The ritonavir C trough also remained significantly higher in older than in younger patients when subjects were stratified with regard to sex, BMI or serum albumin concentration ( Table 2) .
The geometric mean plasma C trough (CV%) of raltegravir was 99 ng/mL (139%), and was comparable between older and younger patients, with no statistically significant difference, as shown in Table 2 . Overall, the raltegravir C trough (CV%) was significantly higher in female patients (108 ng/mL; 123%) than in male patients (94 ng/ mL; 137%; GMR 1.56; 95% CI: 1.29-1.97; P = 0.026), and in patients with BMI < 24 kg/m 2 (112 ng/mL; 135%) than in those with BMI ≥ 24 kg/m 2 (93 ng/mL; 162%; GMR 1.62; 95% CI: 1.31-2.05; P = 0.013). However, there were no significant differences in the raltegravir C trough between patients with high and low albumin concentrations. The raltegravir C trough also remained comparable in older and younger patients when subjects were stratified with regard to sex, BMI or serum albumin concentration (Table 2 ). Neither older nor younger patients presented a CV, coefficient of variation; C trough , plasma trough concentration; BMI, body mass index; albumin, albumin plasma concentration. Data are presented as geometric mean (CV; %).
subtherapeutic C trough of raltegravir. A potentially toxic C trough (> 118 ng/mL) was detected in two patients but this was not associated with any adverse event.
A potential correlation between plasma concentration and a significant increase in the creatine kinase (CK) level (CK > 350 U/L in at least two blood tests in the last 6 months) was investigated for raltegravir. The geometric mean plasma C trough (CV%) of raltegravir was 107 ng/mL (131%) in subjects with, and 94 ng/mL (156%) in those without this abnormality. However, because only three patients (7.1%) presented an increased CK level, this analysis did not reach statistical significance.
Female gender and BMI < 24 kg/m 2 were significantly associated with increased plasma concentrations of both darunavir (C trough > 2200 ng/mL) and raltegravir (C trough > 110 ng/mL) by univariate and multivariate analysis. Albumin concentration < 3.5 g/dL was significantly associated with increased plasma levels of darunavir by both analysis, while it was significantly associated with an increased concentration of raltegravir only by univariate analysis (Table 3) . Finally, no statistically significant correlations were found between mean concentrations of darunavir, ritonavir and raltegravir and immunovirological parameters of HIV infection, the presence of lipodystrophy, and plasma concentrations of total cholesterol, LDL cholesterol and glucose (data not shown).
Discussion
At present, clinical data on the pharmacokinetics of antiretroviral drugs in elderly people are very limited.
Lopinavir plasma concentrations were assessed in 37 subjects aged 18-30 years and 40 subjects aged 45-79 years, who had HIV infection and were na€ ıve to antiretroviral therapy, in the AIDS Clinical Trials Group (ACTG) Protocol 5015, phase II, prospective, cross-sectional comparison study. Patients were treated with lopinavir/ritonavir (400/100 mg twice daily) in combination with emtricitabine (200 mg daily) and stavudine (40 mg daily), and the trough lopinavir concentrations were collected at 24, 36 and 96 weeks after the start of cART. At week 24, older age was associated with a significantly higher median lopinavir C trough (7973 ng/mL in older patients vs. 2700 ng/mL in younger patients; P = 0.041). However, differences in lopinavir concentration between younger and older patients at weeks 36 and 90 were not significant, but a trend towards increasing intrasubject lopinavir C trough was observed over time. Age was negatively associated with lopinavir clearance after adjusting for adherence using a nonlinear, mixed-effects population pharmacokinetic model, so older patients showed higher lopinavir plasma levels as a consequence of probably decreased lopinavir clearance [20] .
The plasma concentrations of atazanavir/ritonavir 300/ 100 mg daily were evaluated in a 24-h intensive pharmacokinetic study in 22 HIV-positive subjects with persistently suppressed HIV RNA. Current cART included atazanavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs) for at least 2 weeks, and the age of 42 years was considered as the cut-off point for the older (> 42 years) patients because 50% of subjects were older than 42 years. The older patients had higher median atazanavir exposure [median area under the plasma concentrationÀtime curve from time 0 to 24 h (AUC 0-24 ) 71.2 mg h/ L; median C trough 1.07 mg/L] than younger subjects (median AUC 0-24 53.1 mg h/L; median C trough 0.78 mg/L). In this study too, older age was associated with slower apparent atazanavir clearance (median 3.5 vs. 4.8 L/h in older vs. younger patients, respectively), which could explain the increased drug plasma levels observed in this subgroup. Moreover, 91% of the older subjects vs. 36% of the younger subjects had atazanavir C trough higher than the proposed upper limit for toxicity (0.85 mg/L), and the multivariate analysis found older age to be the only significant predictor for high atazanavir concentrations [21] .
An unblinded, intensive-sampling pharmacokinetic study enrolled 12 HIV-infected patients aged 55 years or older and treated with tenofovir/emtricitabine plus efavirenz (600 mg daily) or atazanavir/ritonavir (300/100 mg Table 3 Analysis by univariate and multivariate logistic regression of factors associated with increased plasma concentrations of (a) darunavir and (b) raltegravir in the enrolled patients in the univariate and multivariate models; increased plasma concentrations are defined as: (a) C trough > 2200 ng/mL for darunavir, and (b) C trough > 110 ng/mL for raltegravir daily) for at least 2 weeks. Blood plasma and peripheral blood mononuclear cells were collected at 11 time-points over a 24-h dosing interval. The exposure to tenofovir in older subjects was lower than in the general population, with an 8% and a 13% decrease in AUC 0-24 and C max , respectively. There was also a 12% decrease in the AUC 0-24 but a 9% increase in the C max for atazanavir in older individuals, but these changes were not statistically significant. The exposure to emtricitabine and ritonavir was higher in elderly people, with a 19-78% increased AUC 0-24 and C max , while exposure to efavirenz was unchanged [22] . An observational, prospective study evaluated the pharmacokinetic profile of raltegravir in 19 HIV-positive patients over 60 years of age (mean age 66 years) on effective cART and switched to tenofovir/emtricitabine plus raltegravir (400 mg twice daily). After 24 weeks, intensive pharmacokinetic sampling was undertaken in a fasted state and raltegravir concentrations were evaluated. No differences in raltegravir apparent oral clearance and plasma exposure were observed in older subjects in comparison with a younger HIV-infected control group (38 individuals with a mean age of 41 years) [23] .
In our study, we have evaluated the darunavir, ritonavir and raltegravir trough concentrations in 88 HIVinfected patients on stable cART, comparing these concentrations in younger (≤ 40 years) and older (≥ 60 years) patients. This is the first published study, to the best of our knowledge, investigating the pharmacokinetics of darunavir in elderly people.
The geometric mean plasma C trough of darunavir and ritonavir was significantly higher in older subjects than in younger individuals, while the geometric mean plasma C trough of raltegravir was comparable between older and younger subjects. This increase in plasma concentrations of protease inhibitors in elderly people is comparable to that observed in other studies [20, 21] , and probably arises from pharmacokinetic changes which physiologically occur in older subjects, leading to a slower clearance of several drugs. However, raltegravir showed comparable plasma levels in younger and older subjects, as reported by other authors [23] , and its metabolism and excretion are probably less affected by the pharmacokinetic changes occurring in older people.
Moreover, female gender and lower BMI were significantly associated in multivariate analysis with increased plasma concentrations of both darunavir and raltegravir, while a low albumin serum level was significantly associated with an increased plasma concentration of only darunavir. This difference may reflect the lower percentage of drug attached to the serum albumin of raltegravir in comparison with the protease inhibitors, leading to a lower effect of the albumin concentration on raltegravir plasma levels.
Our study has several evident limitations. The observational, open-label design is certainly the main limitation, and the number of enrolled patients was limited, although just enough to detect a difference ≥ 30% in the plasma concentrations between older and younger subjects. The heterogeneity of the enrolled patients makes it difficult to compare our results to those of other similar studies.
The pharmacokinetics of the drugs were assessed by a single time-point measurement (C trough ) and this parameter could not adequately reflect the total plasma exposure to some antiretroviral agents. However, despite a large variation of antiretroviral drug plasma levels, singlemeasurement TDM may be sufficient in routine management to assess whether the drugs' C trough is within the therapeutic plasma level range, as shown by Donnerer et al. [24] . Finally, darunavir/ritonavir is being replaced in clinical practice by darunavir/cobicistat, but the lack of pharmacokinetic data for this new fixed-dose combination in older patients is another limitation of the present study.
Our pharmacokinetic data suggest that no adjustment of raltegravir dosing is required in patients aged 60 years or older, while caution is always necessary when administrating darunavir/ritonavir in subjects aged ≥ 60 years because of an increased plasma exposure to these drugs. In our study, no patients showed a potentially toxic C trough of darunavir/ritonavir at a dosage of 800/100 mg daily, but greater caution should be exercised if a dosage of 600/100 mg twice daily is used in older patients, as a consequence of a potentially more substantial increase in the drugs' plasma levels.
TDM should be considered to monitor the plasma concentrations of darunavir and other ritonavir-boosted protease inhibitors in elderly people, and could probably be useful to avoid excessive plasma exposure to these drugs with the risk of toxicity.
To conclude, data on changes in plasma concentrations of antiretroviral drugs in older patients are still scarce and larger studies are certainly required to better investigate the pharmacokinetics of antiretroviral drugs in the older patient.
